Home >> Tag Archives: Rosetta Genomics—

Tag Archives: Rosetta Genomics—

Rosetta launches next-gen cancer panel

June 3, 2015—Rosetta Genomics has announced the commercial launch of OncoGxOne, Admera Health’s next-generation sequencing panel that detects genetic alterations implicated in cancer to provide clear, concise, and actionable clinical recommendations from a single test. Rosetta said OncoGxOne interrogates all types of genomic aberrations in 64 genes, specifically 56 related to cancer targeted therapy and eight related to chemotherapy. The ...

Read More »

Rosetta Genomics, Precipio commercial partnership, 4/15

April 2015—Rosetta Genomics has entered into a co-promotional commercial partnership with Precipio Diagnostics for the sales and marketing of Precipio’s oncology tests, which include bone marrow and peripheral blood testing for hematological malignancies, such as leukemias and lymphomas. These products are being promoted by Rosetta in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia, and Washington, DC, with an expectation to expand nationally over time.

Read More »

Rosetta Genomics buys PersonalizeDx

April 21, 2015—Rosetta Genomics has agreed to acquire CynoGen, which does business as PersonalizeDx, from Prelude Corp., a Fjord Ventures portfolio company. The acquisition is expected to close within the next several weeks and is contingent upon the closing of Prelude’s purchase of PersonalizeDx from a third party. PersonalizeDx is a rapidly growing molecular diagnostics and services company serving community-based ...

Read More »